Tuesday, October 17, 2017 12:42:00 PM
CEO Michael J. Gelmon
Epicus Communications Group, Inc. EPCG
REVOKED AND DELISTED BY THE SEC
Alberta Securities Commission - Cease Trade Order
CEO Michael J. Gelmon
Focus Gold Corporation
FGLF
REVOKED AND DELISTED BY THE SEC
Alberta Securities Commission - Cease Trade Order
Safeguard Security Holdings, Inc.
Michael J. Gelmon Chairman and President
$0.0001; No Information, Skull & Crossbones
Solar Energy Initiatives, Inc
Michael J. Gelmon CEO
0.0001 x .0002; Stop Sign
Jan 16, 2014 Alberta Securities Commission - Cease Trade Order
Golden Patriot Corp
Michael J. Gelmon President, Secretary, Treasurer, Director
0.0003; No Information, Skull & Crossbones (No trades since 08/05/2014)
Feb 20, 2014 Alberta Securities Commission - Cease Trade Order
Banyan Corp.
Michael J. Gelmon President, Secretary, Treasurer, Director
0.0001; No Information, Skull & Crossbones
Feb 20, 2014 Alberta Securities Commission - Cease Trade Order
Novation Holdings, Inc. f/k/a Allezoe Medical Holdings, Inc (ALZM)
Michael J. Gelmon CEO
Michael Choo, director
Michael B. Holder, director
No bid x 0.0001
Jan 15, 2014 Alberta Securities Commission - Cease Trade Order
There's more:
http://www.thehotpennystocks.com/articles/solar-energy-initiatives-inc-otcmktssnry-takes-a-step-back/
In a previous article we took a brief look at current SNRY CEO Mr. Michael Gelmon’s track record with previous OTC companies where he mostly served as CEO, as well as the total failure those enterprises turned out to be. This list includes Banyan Corp. (OTCMKTS:BNYN), Protocall Technologies, Inc. (OTCMKTS:PCLI), PaperFree Medical Solutions, Inc. (OTCMKTS:PFMS). What those businesses have in common is also the bitter pill of toxic financing which eventually drove them to their current status of around $0.0001 per share, and in the Pink No Information tier.
SNRY‘s own filings contain the name of Asher Enterprises, Inc. – an infamous entity that provided heavily toxic financing for other OTC companies in the past. Combining that with the fact that SNRY recently assumed a fair additional amount of convertible debt from a restaurant business, and then approved a twofold increase of their own authorized shares, the situation leaves very little to the imagination of traders and gives little hope that this latest venture of Mr. Gelmon will be a success.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM